← Allarity Therapeutics, Inc. (ALLR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Allarity Therapeutics, Inc. (ALLR)
Pharmaceutical Preparations · market cap $18M · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Allarity Therapeutics (ALLR) is a 6-employee oncology company with a ~$15M market cap and a Phase 2 pipeline of four programs: 2X-121 in advanced ovarian cancer and metastatic breast cancer, Irofulven in metastatic castration-resistant prostate cancer, and LiPlaCis in advanced or refractory solid tumours. Our data shows $17.0M cash, a 19.9-month runway and $3.9M net debt. The next catalyst on our calendar is an estimated Phase 2 2X-121 event on 2027-03-15, preceded by estimated earnings on 2026-11-13.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
- 2027-03-15 (est.)Phase 2 · 2X-121imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 2X-121 | Phase 2 | Advanced Ovarian Cancer |
| PARP inhibitor 2X-121 | Phase 2 | Metastatic Breast Cancer |
| Irofulven | Phase 2 | Metastatic Castration-Resistant Prostate Cancer Patients |
| LiPlaCis | Phase 2 | Phase 1: Advanced or Refractory Solid Tumours |
Price & technical context
3-month
-29.5%
6-month
-34.7%
12-month
-20.3%
52-wk range
$0.81–$1.77
vs 50-day MA
-8.4%
vs 200-day MA
-19.4%
Realized vol
78.4%
Max drawdown
-59.5%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALLR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.